U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
9048190481A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)TerminatedNo Results AvailablePhotorefractive KeratectomyDrug: diquafosol tetrasodium ophthalmic solution 2%|Drug: placebohttps://ClinicalTrials.gov/show/NCT01381731
9048290482Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain TumorRecruitingNo Results AvailableBrain and Central Nervous System Tumors|Cognitive/Functional Effects|Fatigue|Neurotoxicity|Psychosocial Effects of Cancer and Its TreatmentDrug: modafinil|Other: placebohttps://ClinicalTrials.gov/show/NCT01381718
9048390483Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular LymphomaNot yet recruitingNo Results AvailableLymphomaBiological: rituximab|Genetic: DNA analysis|Genetic: gene expression analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: medical chart reviewhttps://ClinicalTrials.gov/show/NCT01381705
9048490484Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaActive, not recruitingNo Results AvailableCognitive Side Effects of Cancer Therapy|Fatigue|Neurotoxicity Syndrome|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|RecurDrug: Bortezomib|Drug: Dexamethasone|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Biological: Rituximab|Drug: Temsirolimushttps://ClinicalTrials.gov/show/NCT01381692
9048590485Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)CompletedHas ResultsHypercholesterolemiaDrug: Ezetimibehttps://ClinicalTrials.gov/show/NCT01381679
9048690486Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)TerminatedNo Results AvailableInterstitial Lung DiseaseDrug: INS316 solution for inhalation|Drug: hypertonic saline 3% sodium chloride solutionhttps://ClinicalTrials.gov/show/NCT01381666
9048790487An Innovative HIV Prevention Intervention Using Social Networking TechnologyCompletedNo Results AvailableSexual Risk|Substance UseOther: Behavioral: HIV prevention interventionhttps://ClinicalTrials.gov/show/NCT01381653
9048890488A Study to Compare Two Paracetamol TabletsWithdrawnNo Results AvailableHealthy SubjectsDrug: Marketed paracetamol|Drug: Experimental paracetamol formulationhttps://ClinicalTrials.gov/show/NCT01381640
9048990489Safety Evaluation of Dexmedetomidine for EBUS-TBNARecruitingNo Results AvailableLung CancerDrug: Remifentanil|Drug: Dexmedetomidinehttps://ClinicalTrials.gov/show/NCT01381627
9049090490Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)CompletedNo Results AvailableCarcinoma, Renal CellDrug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)https://ClinicalTrials.gov/show/NCT01381614
9049190491Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)CompletedNo Results AvailableCarcinoma, Renal CellDrug: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)https://ClinicalTrials.gov/show/NCT01381601
9049290492The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal WomenCompletedNo Results AvailableOsteoporosis, PostmenopausalOther: Fracture evaluationhttps://ClinicalTrials.gov/show/NCT01381588
9049390493Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old GirlsCompletedHas ResultsInfections, PapillomavirusBiological: GSK Biologicals' HPV vaccine 580299https://ClinicalTrials.gov/show/NCT01381575
9049490494GSK2251052 in the Treatment of Complicated Intra-abdominal InfectionsTerminatedNo Results AvailableInfections, IntestinalDrug: Drug: GSK2251052|Drug: Meropenem|Other: Placebohttps://ClinicalTrials.gov/show/NCT01381562
9049590495GSK2251052 in Complicated Urinary Tract InfectionTerminatedNo Results AvailableInfections, Urinary TractDrug: GSK2251052|Drug: imipenem-cilastatin|Other: Placebohttps://ClinicalTrials.gov/show/NCT01381549
9049690496Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)CompletedNo Results AvailableSystemic Lupus ErythematosusDrug: GSK1550188 1mg/kg or 10mg/kghttps://ClinicalTrials.gov/show/NCT01381536
9049790497A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World DataCompletedNo Results AvailableMigraine DisordersDrug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Single-entity oral triptanshttps://ClinicalTrials.gov/show/NCT01381523
9049890498Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan DatabaseCompletedNo Results AvailableProstatic HyperplasiaDrug: 5-alpha Reductase Inhibitor (5ARI)https://ClinicalTrials.gov/show/NCT01381510
9049990499Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan MonotherapyCompletedNo Results AvailableMigraine DisordersDrug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Triptan monotherapyhttps://ClinicalTrials.gov/show/NCT01381497
9050090500Argireline in Treatment of Periorbital WrinklesCompletedNo Results AvailableWrinklesDrug: 10% Argirelinehttps://ClinicalTrials.gov/show/NCT01381484
9050190501Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedHas ResultsPulmonary Disease, Chronic ObstructiveDrug: fluticasone propionate/salmeterol xinafoate combinationhttps://ClinicalTrials.gov/show/NCT01381471
9050290502Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post ExacerbationCompletedNo Results AvailablePulmonary Disease, Chronic ObstructiveDrug: FSC|Drug: ACshttps://ClinicalTrials.gov/show/NCT01381458
9050390503A Study Assessing GW870086X's Potential to Cause Skin ThinningCompletedNo Results AvailableDermatitis, AtopicDrug: GW870086X 0.2%|Drug: GW870086X 2%|Drug: Clobetasol Propionate|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01381445
9050490504Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)CompletedNo Results AvailableLiver DiseasesDrug: Azathioprinehttps://ClinicalTrials.gov/show/NCT01381432
9050590505First Time in Human Study (FTIH) With Positron Emission Tomography (PET)CompletedNo Results AvailableSchizophrenia|Healthy VolunteerDrug: GSK1144814|Drug: GSK1144814|Drug: GSK1144814https://ClinicalTrials.gov/show/NCT01381419
9050690506Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing ExacerbationsCompletedHas ResultsPulmonary Disease, Chronic ObstructiveDrug: TIO|Drug: TIO+FSChttps://ClinicalTrials.gov/show/NCT01381406
9050790507BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )CompletedNo Results AvailableOsteoporosisDrug: Ibandronatehttps://ClinicalTrials.gov/show/NCT01381393
9050890508Manual Therapy Treatment for Myofascial PainCompletedNo Results AvailableMyofascial Pain SyndromesProcedure: Manual therapyhttps://ClinicalTrials.gov/show/NCT01381380
9050990509PPSV23 Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease (COPD)CompletedNo Results AvailableChronic Obstructive Pulmonary DiseaseBiological: PPSV23 pneumococcal vaccine (Pneumovax®)|Drug: Normal Salinehttps://ClinicalTrials.gov/show/NCT01381367
9051090510Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)Active, not recruitingNo Results AvailableMultiple SclerosisOther: Progressive exercise|Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Other: Modified paleolithic diet|Dietary Supplement: Omega 3 fatty acids|Dietary Supplement: Full Spectrum vitamin|Dietary Supplement: Essential - hydroxytyrosol|Dietary Supplement: Maltodextrin fiber supplement|Dietary Supplement: Mineral boost (magnesium)|Dietary Supplement: Niacinamide|Dietary Supplement: Methyl B12|Dietary Supplement: Taurine|Dietary Supplement: creatine|Dietary Supplement: thiamine|Dietary Supplement: riboflavin|Dietary Supplement: N acetylcysteine|Dietary Supplement: alpha lipoic acid|Dietary Supplement: L acetyl carnitine|Dietary Supplement: methyl folate|Dietary Supplement: coenzyme Q|Behavioral: meditation|Behavioral: self massage|Behavioral: learning|Dietary Supplement: Coconut oilhttps://ClinicalTrials.gov/show/NCT01381354

* Görseller ve İçerik tekif hakkına sahip olabilir